Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Genfit
Pharma
With trial success, Gilead paves way for broader use of Livdelzi
A phase 3 study of Gilead’s Livdelzi has met its primary endpoint, showing its ability to help more patients with primary biliary cholangitis.
Kevin Dunleavy
Jun 2, 2026 10:55am
FDA approves Gilead's Livdelzi for primary biliary cholangitis
Aug 14, 2024 3:29pm
With FDA nod for Iqirvo, Ipsen and Genfit will take on Intercept
Jun 11, 2024 11:07am
Novo Nordisk's semaglutide misses the mark in NASH study
Jun 29, 2022 10:53am
